steviol and Diabetes-Mellitus

Stevia rebaudiana Bertoni is a sweet and nutrient-rich plant belonging to the Asteraceae family. Stevia leaves contain steviol glycosides including stevioside, rebaudioside (A to F), steviolbioside, and isosteviol, which are responsible for the plant's sweet taste, and have commercial value all over the world as a sugar substitute in foods, beverages and medicines. Among the various steviol glycosides, stevioside, rebaudioside A and rebaudioside C are the major metabolites and these compounds are on average 250-300 times sweeter than sucrose. Steviol is the final product of Stevia metabolism. The metabolized components essentially leave the body and there is no accumulation. Beyond their value as sweeteners, Stevia and its glycosdies possess therapeutic effects against several diseases such as cancer, diabetes mellitus, hypertension, inflammation, cystic fibrosis, obesity and tooth decay. Studies have shown that steviol glycosides found in Stevia are not teratogenic, mutagenic or carcinogenic and cause no acute and subacute toxicity. The present review provides a summary on the biological and pharmacological properties of steviol glycosides that might be relevant for the treatment of human diseases.

Topics: Cystic Fibrosis; Dental Caries; Diabetes Mellitus; Diterpenes, Kaurane; Glycosides; Humans; Hypertension; Inflammation; Neoplasms; Obesity; Plant Extracts; Stevia

Topics: Diabetes Mellitus; Diterpenes, Kaurane; Humans; Prevalence; Sweetening Agents; Treatment Outcome

There are more published dietary exposure data for intense sweeteners than for any other group of food additives. Data are available for countries with different patterns of sweetener approvals and also for population groups with high potential intakes, such as children and diabetic subjects. These data provide a secure basis for predicting the potential intakes of a novel intense sweetener by adjustment of the reported intakes of different sweeteners in mg/kg body weight by their relative sweetness intensities. This approach allows the possibility that a novel sweetener attains the same pattern and extent of use as the existing sweeteners. The intakes by high consumers of other sweeteners allows for possible brand loyalty to the novel sweetener. Using this method, the estimated dietary exposures for rebaudioside A in average and high consumers are predicted to be 1.3 and 3.4mg/kg body weight per day for the general population, 2.1 and 5.0mg/kg body weight per day for children and 3.4 and 4.5mg/kg body weight per day for children with diabetes. The temporary ADI defined by the JECFA for steviol glycosides [JECFA, 2005. Steviol glycosides. In: 63rd Meeting of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization (WHO), Geneva, Switzerland, WHO Technical Report Series 928, pp. 34-39] was set at 0-2mg/kg body weight (expressed as steviol equivalents); after correction for the difference in molecular weights, these estimated intakes of rebaudioside A are equivalent to daily steviol intakes of less than 2mg/kg. In consequence, this analysis shows that the intakes of rebaudioside A would not exceed the JECFA temporary ADI set for steviol glycosides.

Topics: Adolescent; Adult; Body Weight; Child; Child, Preschool; Diabetes Mellitus; Diet; Dietary Sucrose; Diterpenes, Kaurane; Humans; Sweetening Agents